Switch theme
Sign up to access all valuation multiples
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
2014
5.9K+
LTM Revenue $2.1B
LTM EBITDA $478M
$8.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medpace has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $478M.
In the most recent fiscal year, Medpace achieved revenue of $2.1B and an EBITDA of $476M.
Medpace expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medpace valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Profit | $668M | XXX | $656M | XXX | XXX | XXX |
| Gross Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | $478M | XXX | $476M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $448M | XXX | $447M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $399M | XXX | $404M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medpace's stock price is $295.
Medpace has current market cap of $8.5B, and EV of $8.2B.
See Medpace trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.2B | $8.5B | XXX | XXX | XXX | XXX | $12.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medpace has market cap of $8.5B and EV of $8.2B.
Medpace's trades at 3.9x EV/Revenue multiple, and 17.1x EV/EBITDA.
Equity research analysts estimate Medpace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medpace has a P/E ratio of 21.2x.
See valuation multiples for Medpace and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.5B | XXX | $8.5B | XXX | XXX | XXX |
| EV (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 17.1x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBIT | 18.2x | XXX | 18.2x | XXX | XXX | XXX |
| EV/Gross Profit | 12.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 20.9x | XXX | XXX | XXX |
| EV/FCF | 15.9x | XXX | 14.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedpace's last 12 month revenue growth is 3%
Medpace's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $35K for the same period.
Medpace's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medpace's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medpace and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medpace acquired XXX companies to date.
Last acquisition by Medpace was XXXXXXXX, XXXXX XXXXX XXXXXX . Medpace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medpace founded? | Medpace was founded in 2014. |
| Where is Medpace headquartered? | Medpace is headquartered in United States of America. |
| How many employees does Medpace have? | As of today, Medpace has 5.9K+ employees. |
| Who is the CEO of Medpace? | Medpace's CEO is Mr. August J. Troendle, M.D.. |
| Is Medpace publicy listed? | Yes, Medpace is a public company listed on NAS. |
| What is the stock symbol of Medpace? | Medpace trades under MEDP ticker. |
| When did Medpace go public? | Medpace went public in 2016. |
| Who are competitors of Medpace? | Similar companies to Medpace include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Medpace? | Medpace's current market cap is $8.5B |
| What is the current revenue of Medpace? | Medpace's last 12 months revenue is $2.1B. |
| What is the current revenue growth of Medpace? | Medpace revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Medpace? | Current revenue multiple of Medpace is 3.8x. |
| Is Medpace profitable? | Yes, Medpace is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medpace? | Medpace's last 12 months EBITDA is $478M. |
| What is Medpace's EBITDA margin? | Medpace's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Medpace? | Current EBITDA multiple of Medpace is 17.1x. |
| What is the current FCF of Medpace? | Medpace's last 12 months FCF is $512M. |
| What is Medpace's FCF margin? | Medpace's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Medpace? | Current FCF multiple of Medpace is 15.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
